Does nebivolol prevent contrast-induced nephropathy in humans?

Area of Science:

• Cardiology
• Nephrology
• Pharmacology

Background:

• Experimental studies suggest nebivolol is effective for contrast-induced nephropathy (CIN) prophylaxis.
• Nebivolol possesses vasodilatory and antioxidant properties, hypothesised to protect renal function.

Purpose of the Study:

• To evaluate the protective effects of prophylactic nebivolol on renal function in patients undergoing procedures with iodinated contrast agents.
• To compare the efficacy of nebivolol, N-acetylcysteine, and hydration alone in preventing CIN.

Main Methods:

• A study involving 120 patients scheduled for coronary angiography and ventriculography.
• Patients were divided into three groups: N-acetylcysteine, nebivolol, or hydration alone.
• Primary endpoint was CIN occurrence; secondary endpoint was serum creatinine level changes at 2 and 5 days post-contrast.

Main Results:

• CIN incidence was 22.5% with N-acetylcysteine, 20.0% with nebivolol, and 27.5% with hydration alone (P = 0.72).
• Serum creatinine levels did not significantly change at 2 days post-contrast in any group.
• At 5 days, significant increases in creatinine were observed in the N-acetylcysteine and hydration groups, but not in the nebivolol group (P=0.06).

Conclusions:

• Pretreatment with nebivolol appears to be protective against the nephrotoxic effects of contrast media.
• Nebivolol may be a viable option for CIN prophylaxis, warranting further investigation.